Status:
UNKNOWN
Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children
Lead Sponsor:
National Liver Institute, Egypt
Conditions:
Refractory Ascites
Children, Only
Eligibility:
All Genders
7-18 years
Phase:
NA
Brief Summary
Ascites in liver cirrhosis is explained by increased production of vasoactive substances leading to renal vasoconstriction and salt and water retention. The retained water then accumulates in the peri...
Detailed Description
Ascites in liver cirrhosis is explained by increased production of vasoactive substances, such as nitric oxide, carbon monoxide, and endocannabinoids, which cause splanchnic vasodilatation, increased ...
Eligibility Criteria
Inclusion
- Children aged 7-18 years
- Both sexes
- Having refractory ascites (not responding to maximal dose of diuretics
- Diuretic-induced complications necessitate discontinuation of the drug
Exclusion
- Non-cirrhotic causes of ascites
- Intrinsic renal disease ( e.g; polycystic kidney disease)
- Active gastrointestinal bleeding or the presence of risky varices
- Patients with Portal vein thrombosis and Budd-Chiari
- Cardiovascular disease
- Systemic hypertension or prehypertension
- Hyperthyroidism
- Patients with narrow-angle glucoma
Key Trial Info
Start Date :
June 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04043858
Start Date
June 5 2020
End Date
December 1 2021
Last Update
August 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Hepatology, Gastroenterology and Nutrition Department, National Liver Institute, Menoufia University
Shibīn al Kawm, Menofiya, Egypt, 32511